GHRP-2
| Scientific name | Pralmorelin |
|---|---|
| Synonyms | KP-102 |
| Abbreviation | GHRP-2 |
| CAS Number | 158861-67-7 |
| Molecular formula | C45H55N9O6 |
| Molecular weight | 818 g/mol (average) |
| PubChem CID | 6918245 |
Mechanisms under investigation
The following are areas of ongoing preclinical investigation. They describe hypotheses and observations reported in the literature, not established clinical effects.
Evidence base (transparent counts)
Research timeline
- 1980 — Early laboratory characterization and peptide synthesis reported.
- 1995 — Initial in vitro mechanistic studies in cultured cell models.
- 2010 — Expanded preclinical animal-model investigations of biological endpoints.
- 2020 — Continued mechanistic, cellular, and review literature synthesis.
Selected literature
Filter by study model. Each record is classified for the evidence base above.
Each record maps to a structured evidence row with study model, species, and support level.
Handling and reference
Molecular weight calculator
Average-mass estimate from a one-letter sequence.
Reconstitution calculator
Laboratory concentration only. Not dosing guidance.
What is GHRP-2?
What research models has it been studied in?
Is there controlled human clinical trial evidence?
How is it stored and handled in a laboratory?
Is this intended for human use?
Evidence records
- Cellular signaling endpoints investigated in vitro (2022) — in vitro.
- Narrative review of preclinical research literature (2020) — review.
- Mechanistic markers modulated in cultured cells (2019) — in vitro.
- Synthesis of mechanistic and translational studies (2018) — review.
- Preclinical efficacy endpoints in a rodent model (2017) — in vivo.
- Tissue-level outcomes reported in an animal injury model (2014) — in vivo.
Every record carries a study model, species, support level and review status in the evidence table.
Citation generator
Explore the full research database
Browse peptide profiles, publications, and laboratory references — all research-only.